Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.
------------------------------------------------------------
July 26, 2002
U.S. IMMUNIZATION NEWS
"Therapeutic Cancer Vaccines on Trial"
Nature Biotechnology (www.nature.com/nbt) (07/02) Vol. 20, No. 7, P. 659; Reichert, Janice M.; Paquette, Cherie
A disadvantage of standard cancer therapies is that healthy cells are destroyed, while newer antibody-based treatments have a high relapse rate. Therapeutic cancer vaccines may offer the best benefits for cancer patients. The vaccines work by stimulating the production of anti-tumor antibodies and cytotoxic T lymphocytes by the immune system. The antigens or whole cells used in the vaccines are either acquired from the patient or a human donor. Twenty-eight new companies entered the therapeutic cancer vaccine market from 1993 to 2001. Three U.S-made vaccines are currently in Phase III trials, and three are already marketed in Europe. The major disadvantage of the products is that that cancer is too individualized for a optimal treatment to be available for every patient.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.